Natural Product (NP) Details
| General Information of the NP (ID: NP0873) | |||||
|---|---|---|---|---|---|
| Name |
Gentiopicroside
|
||||
| Synonyms |
Gentiopicroside; Gentiopicrin; 20831-76-9; UNII-0WE09Z21RC; 0WE09Z21RC; CHEBI:5321; Gentiopicroside, >=98% (HPLC); (5R,6S)-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-5-vinyl-5,6-dihydro-1H,3H-pyrano[3,4-c]pyran-1-one; 1H,3H-Pyrano[3,4-c]pyran-1-one, 5-ethenyl-6-(beta-D-glucopyranosyloxy)-5,6-dihydro-, (5R,6S)-; Gentiopicrin,(S); (3S,4R)-4-ethenyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,6-dihydro-3H-pyrano[3,4-c]pyran-8-one; (5R,6S)-6-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-5-vinyl-5,6-dihydropyrano[3,4-c]pyran-1(3H)-one; MLS002473254; SCHEMBL154304; CHEMBL508320; MEGxp0_000872; POLYPROPYLENEGLYCOL4000; ACon1_001284; DTXSID40878043; HMS2198G10; HY-N0494; ZINC4098340; EINECS 244-070-2; MFCD00075700; s3777; ZB1867; AKOS015896721; CCG-268110; LMPR0102070009; NSC 606402; NCGC00180669-01; 1H,3H-Pyrano(3,4-c)pyran-1-one, 5-ethenyl-6-(beta-D-glucopyranosyloxy)-5,6-dihydro-, (5R-trans)-; AC-20248; AS-74360; O673; SMR001397341; CS-0009015; N1898; C09782; 831G769; BRD-K33131085-001-01-5; Q27106718; (5R,6S)-5-ethenyl-6-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1H,3H,5H,6H-pyrano[3,4-c]pyran-1-one; (5R,6S)-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-5-vinyl-5,6-dihydropyrano[3,4-c]pyran-1(3H)-one; (5R-trans)-6-(??-D-glucopyranosyloxy)-5,6-dihydro-5-vinyl-1H,3H-pyrano[3,4-c]pyran-1-one; (5R-trans)-6-(beta-D-Glucopyranosyloxy)-5,6-dihydro-5-vinyl-1H,3H-pyrano(3,4-c)pyran-1-one
Click to Show/Hide
|
||||
| Species Origin | Gentiana ... | Click to Show/Hide | |||
| Gentiana | |||||
| Acetylenic spiroketal enol | |||||
| Disease | Investigative | ||||
| Chronic kidney disease [ICD-11: GB61] | Investigative | [1] | |||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.864
MDCK Permeability
-4.948
PAMPA
+++
HIA
++
Distribution
VDss
-0.558
PPB
53.5%
BBB
- -
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- - -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
- - -
CYP2C9 inhibitor
- - -
CYP2C9 substrate
++
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
- - -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
+++
HLM Stability
- - -
Excretion
CLplasma
2.108
T1/2
2.07
Toxicity
DILI
+++
Rat Oral Acute Toxicity
- -
FDAMDD
- -
Respiratory
- - -
Human Hepatotoxicity
++
Ototoxicity
+++
Drug-induced Nephrotoxicity
++
Drug-induced Neurotoxicity
- -
Hematotoxicity
++
Genotoxicity
+++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C16H20O9
|
||||
| PubChem CID | |||||
| Canonical SMILES |
C=CC1C(OC=C2C1=CCOC2=O)OC3C(C(C(C(O3)CO)O)O)O
|
||||
| InChI |
1S/C16H20O9/c1-2-7-8-3-4-22-14(21)9(8)6-23-15(7)25-16-13(20)12(19)11(18)10(5-17)24-16/h2-3,6-7,10-13,15-20H,1,4-5H2/t7-,10-,11-,12+,13-,15+,16+/m1/s1
|
||||
| InChIKey |
DUAGQYUORDTXOR-GPQRQXLASA-N
|
||||
| CAS Number |
CAS 20831-76-9
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
| Leflunomide + Methotrexate | Click to Show/Hide the Molecular Data of This Drug | |||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | IL1B | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | SD rats (200 g +/- 20 g) were used in this study. | |||||
| Experimental
Result(s) |
Gentiopicroside (GPS) could exert hepatoprotective effects on leflunomide (LEF)- and/or methotrexate (MTX)-treated arthritic rats. | |||||
